PAVmed Insider: President & CFO Receives 150K Restricted Shares, Owns 200,834

Rhea-AI Filing Summary

PAVmed Inc. (PAVM) reporting person Dennis M. McGrath, who is identified as President and CFO, received a grant of 150,000 shares of restricted common stock on 09/30/2025. The shares were granted under the company's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan and carry a single vesting date of May 20, 2028; they are subject to forfeiture if the required service period is not completed. The Form 4 shows 200,834 shares beneficially owned by the reporting person after the transaction. The reported transaction lists a price of $0, indicating these were restricted shares rather than a cash purchase. The filing was executed by power of attorney and dated 10/02/2025.

Positive

• 150,000 restricted shares granted with a single vesting date of May 20, 2028 supporting executive retention
• 200,834 shares beneficially owned following the grant, indicating meaningful insider equity ownership

Negative

• None.

Insights

Corporate Governance & Compensation Analyst

TL;DR: Officer received 150,000 restricted shares vesting in May 2028, aligning pay with future service.

The grant of 150,000 restricted shares to the company’s President and CFO ties compensation to continued employment through May 20, 2028. Such time‑based restricted stock is governance‑oriented, reinforcing retention rather than immediate liquidity.

The filing reports 200,834 shares beneficially owned after the grant, which quantifies the officer’s current equity stake disclosed on the Form 4. The $0 price entry confirms these are restricted awards, not a market purchase.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

MCGRATH DENNIS M

(Last) (First) (Middle)

360 MADISON AVENUE, 25TH FLOOR

(Street)

NEW YORK NY 10017

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PAVmed Inc. [ PAVM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CFO

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/30/2025		A		150,000(1)	A	$0(1)	200,834	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock granted to the reporting person under the issuer's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan with a single vesting date of May 20, 2028. Such restricted stock is subject to forfeiture if the requisite service period is not completed.

	/s/ Michael A. Gordon, by power of attorney	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the PAVmed (PAVM) Form 4 report?

The Form 4 reports that Dennis M. McGrath, the company’s President and CFO, was granted 150,000 restricted shares on 09/30/2025.

When do the restricted shares awarded to the PAVM officer vest?

The restricted shares have a single vesting date of May 20, 2028 and are subject to forfeiture if the service period is not completed.

How many PAVM shares does the reporting person own after the transaction?

The Form 4 shows the reporting person beneficially owns 200,834 shares following the reported transaction.

Was cash paid for the shares reported on the PAVM Form 4?

No cash was reported; the transaction lists a price of $0, indicating these were restricted stock awards.

Who signed the PAVM Form 4 filing and when?

The filing was signed by Michael A. Gordon by power of attorney on 10/02/2025.